期刊
BIOMOLECULES
卷 11, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/biom11040526
关键词
RAGE; pancreatic cancer; gemcitabine; cachexia
资金
- College of Health Professions at NDSU
- NIH [P30GM103332, P20GM109024, U54GM128729]
- National Institute of General Medicine (NIGMS)
Studies have shown that RAGE plays a critical role in promoting pancreatic cancer cell proliferation and resistance to gemcitabine. Blocking the RAGE/HMGB1 interaction can enhance the cytotoxic effect of gemcitabine, reduce autophagy, and protect against excessive weight loss during treatment.
Pancreatic ductal adenocarcinoma (PDAC) remains a very difficult cancer to treat. Recent in vitro and in vivo studies suggest that the activation of the receptor for advanced glycation end products (RAGE) by its ligands stimulates pancreatic cancer cell proliferation and tumor growth. Additional studies show that, in the RAGE ligand, the high mobility group box 1 (HMGB1) protein plays an important role in chemoresistance against the cytotoxic agent gemcitabine by promoting cell survival through increased autophagy. We hypothesized that blocking the RAGE/HMGB1 interaction would enhance the cytotoxic effect of gemcitabine by reducing cell survival and autophagy. Using a preclinical mouse model of PDAC and a monoclonal antibody (IgG 2A11) as a RAGE inhibitor, we demonstrate that RAGE inhibition concurrent with gemcitabine treatment enhanced the cytotoxic effect of gemcitabine. The combination of IgG 2A11 and gemcitabine resulted in decreased autophagy compared to treatment with gemcitabine combined with control antibodies. Notably, we also observed that RAGE inhibition protected against excessive weight loss during treatment with gemcitabine. Our data suggest that the combination of gemcitabine with a RAGE inhibitor could be a promising therapeutic approach for the treatment of pancreatic cancer and needs to be further investigated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据